A census of amplified and overexpressed human cancer genes

Futreal PA. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).

Bignell GR. et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res. 17, 1296–1303 (2007).

Savelyeva L. & Schwab M. Amplification of oncogenes revisited: from expression profiling to clinical application. Cancer Lett. 167, 115–123 (2001).

Myllykangas S. & Knuutila S. Manifestation, mechanisms and mysteries of gene amplifications. Cancer Lett. 232, 79–89 (2006).

Schwab M. Oncogene amplification in solid tumors. Semin. Cancer Biol. 9, 319–325 (1999).

Natrajan R. et al. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors. Clin. Cancer Res. 12, 7284–7293 (2006).

McIntyre A. et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 65, 8085–8089 (2005).

Fix A. et al. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosom. Cancer 47, 819–834 (2008).

Weber A, Imisch P, Bergmann E & Christiansen H. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J. Clin. Oncol. 22, 2681–2690 (2004).

Kaneko S., Ohira M, Nakamura Y, Isogai E, Nakagawara A & Kaneko M. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. J. Cancer Res. Clin. Oncol. 133, 185–192 (2007).

De Preter K. et al. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J. Clin. Oncol. 23, 3167–3168 (2005).

Rodriguez S. et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene 22, 1880–221891 (2003).

Zafarana G. et al. 12p-amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH. Oncogene 22, 7695–7701 (2003).

Bourdon V. et al. Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. Cancer Res. 62, 6218–6223 (2002).

Ormandy CJ, Musgrove EA, Hui R., Daly RJ & Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 78, 323–335 (2003).

Albertson DG. Gene amplification in cancer. Trends Genet. 22, 447–455 (2006).

Cordon-Cardo C. et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54, 794–799 (1994).

Hayward NK. Genetics of melanoma predisposition. Oncogene 22, 3053–3062 (2003).

Feber A. et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23, 1627–1630 (2004).

Oeggerli M. et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23, 5616–5623 (2004).

Kao J. & Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosom. Cancer 45, 761–769 (2006).

Comoglio PM, Giordano S. & Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Rev. Drug Discov. 7, 504–516 (2008).

Zender L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253–1267 (2006).

Vogel CL. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).

Mass RD. et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 6, 240–246 (2005).

Ray ME. et al. Genomic and expression analysis of the 8p11–12 amplicon in human breast cancer cell lines. Cancer Res. 64, 40–47 (2004).

Garcia MJ. et al. A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes. Oncogene 24, 5235–5245 (2005).

Reis-Filho JS. et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 12, 6652–6662 (2006).

Campbell PJ. et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nature Genet. 40, 722–729 (2008).

Sugawa N., Ekstrand AJ, James CD & Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl Acad. Sci. USA 87, 8602–8606 (1990).

Weber-Hall S. et al. Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. Genes Chromosom. Cancer 17, 7–13 (1996).

Nikolsky Y. et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 68, 9532–9540 (2008).